Abstract:ImportanceLupus nephritis (LN) is typically treated with intravenous cyclophosphamide (IVCY), which is associated with serious adverse effects. Tacrolimus may be an alternative for initial treatment of LN; however, large-scale, randomized clinical studies of tacrolimus are lacking.ObjectiveTo assess efficacy and safety of tacrolimus vs IVCY as an initial therapy for LN in China.Design, Setting, and ParticipantsThis randomized (1:1), open-label, parallel-controlled, phase 3, noninferiority clinical trial recruited patients aged 18 to 60 years with systemic lupus erythematosus and LN class III, IV, V, III+V, or IV+V primarily from outpatient settings at 35 centers in China. Inclusion criteria included body mass index of 18.5 or greater to less than 27, 24-hour urine protein of 1.5 g or greater, and serum creatinine of less than 260 μmol/L. Of 505 patients screened, 191 failed screening (163 ineligible, 25 withdrawn consent, and 3 other reasons). Overall, 314 were randomized. The first patient was enrolled March 10, 2015, and the study finished September 13, 2018. The follow-up period was 24 weeks. Data were analyzed from December 2019 to March 2020.InterventionsOral tacrolimus (target trough level, 4-10 ng/mL) or IVCY for 24 weeks plus prednisone.Main Outcomes and MeasuresComplete or partial response rate at week 24 (prespecified).ResultsA total of 314 patients were randomized (158 [50.3%] to tacrolimus and 156 [49.7%] to IVCY). Overall, 299 patients (95.2%) were treated (tacrolimus group, 157 [52.5%]; IVCY group, 142 [47.5%]). Baseline demographic and clinical characteristics were generally similar between groups (mean [SD] age, 34.2 [9.5] years; 262 [87.6%] female). Tacrolimus was found to be noninferior to IVCY for LN response at week 24. There was a complete or partial response rate of 83.0% (117 of 141 patients) in the tacrolimus group and 75.0% (93 of 124 patients) in the IVCY group (difference, 7.1%; 2-sided 95% CI, −2.7% to 16.9%; lower limit of 95% CI greater than −15%). At week 24, least-square mean change in Systemic Lupus Erythematosus Disease Activity Index score was −8.6 with tacrolimus and −6.4 with IVCY (difference, −2.2; 95% CI, −3.1 to −1.3). Changes in other immune parameters and kidney function were generally similar between groups. Serious treatment-emergent adverse events (TEAEs) were reported in 29 patients in the tacrolimus group (18.5%) and 35 patients in the IVCY group (24.6%). Most common serious study drug-related TEAEs were infections (14 [8.9%] and 23 [16.2%], respectively). Seven patients in each group withdrew due to AEs.Conclusions and RelevanceIn this study, oral tacrolimus appeared noninferior to IVCY for initial therapy of active LN, with a more favorable safety profile than IVCY. Tacrolimus may be an alternative to IVCY as initial therapy for LN.Trial RegistrationClinicalTrials.gov Identifier:NCT02457221

Comparison of Different Uses of Cyreinishosphattlide in Lupus Nephritis: A IVIeta-Analysis of Randomized Controlled Trials

Comparison of Different Usage of Cyclophosphamide in Lupus Nephritis: A Meta-analysis of Randomized Controlled Trails

Combined Immunosuppressive Treatment (CIST) in Lupus Nephritis: a Multicenter, Randomized Controlled Study.

Comparison of Short Interval and Low Dose (SILD) with High Dose of Cyclophosphamide in the Susceptibility to Infection in SLE: a Multicentrereal-World Study

Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study

Comparison study of Leflunomide and Cyclophosphamide on lupus nephritis

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.

Network Meta-analysis of long-term usage of different immunosuppressants combined with glucocorticoids in the treatment of systemic lupus erythematosus nephritis

Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study

Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study

The Effect of Calcineurin Inhibitors in the Induction and Maintenance Treatment of Lupus Nephritis: a Systematic Review and Meta-Analysis.

The Efficacy And Safety Of Leflunomide For The Treatment Of Lupus Nephritis In Chinese Patients: Systematic Review And Meta-Analysis

Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial

Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis

Efficacy of low-dose leflunomide in lupus nephritis: A multi-center prospective study

Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis

Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials

Mycophenolate Mofetil or Tacrolimus Compared with Intravenous Cyclophosphamide in the Induction Treatment for Active Lupus Nephritis

Impact of dosing strategy on clinical outcomes of patients with lupus nephritis initially treated with lower-than-recommended-dose cyclophosphamide

Mizoribine Versus Mycophenolate Mofetil or Intravenous Cyclophosphamide for Induction Treatment of Active Lupus Nephritis.

Efficacy and Safety of Cyclophosphamide Combined with Mycophenolate Mofetil for Induction Treatment of Class IV Lupus Nephritis.